Item 5.07 Submission of Matters to a Vote of Security Holders.

Aerovate Therapeutics, Inc. (the "Company") held its 2023 Annual Meeting of Stockholders (the "Annual Meeting") on June 6, 2023. As of April 14, 2023, the record date for the Annual Meeting, there were 24,850,842 shares of the Company's common stock outstanding and entitled to vote at the Annual Meeting. The Company's stockholders voted on the following matters, which are described in detail in the Company's Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 19, 2023: (i) to elect each of Allison Dorval and Joshua Resnick, M.D. as a Class II member of the board of directors, to serve until the Company's 2026 Annual Meeting of Stockholders and until her or his successor is duly elected and qualified ("Proposal 1"), and (ii) to ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 ("Proposal 2").

Proposal 1 - Election of Class II Director Nominees

The Company's stockholders approved the Class II director nominees recommended for election in Proposal 1 at the Annual Meeting. The results of Proposal 1 were as follows:





                                                           Broker

Class II Director Nominee Votes For Votes Withheld Non-Votes Allison Dorval

              18,685,353      366,333       2,132,996

Joshua Resnick, M.D. 18,169,764 881,922 2,132,996

Proposal 2 - Ratification of Appointment of the Company's Independent Registered Public Accounting Firm

The Company's stockholders ratified the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of Proposal 2 were as follows:



Votes For    Votes Against   Abstain Broker Non-Votes
21,184,481         0           201          0

No other matters were submitted to or voted on by the Company's stockholders at the Annual Meeting.

© Edgar Online, source Glimpses